EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ferroptosis in Pneumoconiosis: From Molecular and Cellular Mechanisms to Therapeutic Strategies

Mengli Yan, Jing Zhang, Gaili Ji, Xiaobin Fang, Chunheng Mo

Med Research · 2025-09 · 1 (2) · 239-256

DOI: 10.1002/mdr2.70020 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Pneumoconiosis, caused by exposure to inorganic hazardous materials, is a highly prevalent and severe occupational disease. It is characterized by a progressive inflammatory process and the development of permanent lung fibrosis, which ultimately can lead to respiratory failure and mortality. Ferroptosis is a non‐apoptotic, regulated cell death pathway driven by iron‐of dependent accumulation membrane‐localized lipid peroxides. It acts as a promoting mechanism and participates in the biological processes of pneumoconiosis. Notably, alveolar macrophages, epithelial cells, and endothelial cells exhibit exquisite vulnerability to ferroptosis, highlighting targeting this process as a promising treatment approach for pneumoconiosis. Thus, a comprehensive and in‐depth understanding of the role of ferroptosis in pneumoconiosis is critical to enable the successful clinical translation of ferroptosis‐targeted therapies. In this review, we provide an overview of the recent advancements in understanding ferroptosis in pneumoconiosis, covering molecular mechanisms, regulatory pathways and biological functions. We also summarize the potential applications of ferroptosis inhibition for pneumoconiosis treatment across pulmonary cell populations. We finally discuss the current challenges and future directions of ferroptosis in the treatment of pneumoconiosis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →